Fig. 5

MT worked against MP-induced ferroptosis in BMSC. A, B DEGs and GSEA analysis. GSE112101 is RNA-seq data including nine cell populations from humans after in vitro exposure to MP (8500 μg/L, 22.7 μM) for two time points, 2 h and 6 h. Here, we selected 2 h and 6 h of osteoblast RNA-seq to conduct DEGs and GSEA analysis. (|log(2)(fold change)|≥ 1, p value ≤ 0.05). C MDA detection. D Flow cytometry analysis of C11-BODIPY staining. (Excitation: 500 nm, emission: 510 nm) E Quantitative analysis of C11-BODIPY oxidation. F Flow cytometry analysis of mitochondrial potential through JC-1. (Excitation: 585 nm, emission: 590 nm) G Quantitative analysis of JC-1. H After treatment with 100 µM MP and 10 µM MT or 100 µM MT for 72 h, BMSC was collected for western blot analysis. I–K The fold change in the relative gray levels of ACSL4, SLC7a11 and GPX4 compared to the no intervention group. (β-actin was selected as an internal reference.) L–N. qPCR analysis of Acsl4, Slc7a11 and Gpx4 expression in BMSC. (β-actin was selected as an internal reference.) (*p < 0.05 and **p < 0.01 compared with the 100 μM MP treatment group. Full-length blots are presented in Additional file 2: Figures S3–S6.)